Drug Profile
Research programme: therapeutics - BioStem Technologies/CCM Pharma Solutions
Alternative Names: BSEM-120; BSEM-125; BSEM-130; BSEM-135; BSEM18-120; BSEM18-125; BSEM18-130; BSEM18-135Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator BioStem Technologies; CCM Pharma Solutions
- Class Antihypertensives; Antipsychotics; Cardiovascular therapies; Neuroprotectants
- Mechanism of Action ACE inhibitors; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; CNS disorders; Hypertension; Metabolic disorders; Schizophrenia
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Hypertension in Malaysia (PO, Liquid)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Hypertension in USA (PO, Liquid)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Schizophrenia in Malaysia (PO, Liquid)